You are using an outdated browser. Please upgrade your browser to improve your experience and security.

Identifying secondary AML (sAML)

Therapy-related AML (t-AML)1

WHO defines t-AML as AML that arises from prior cytotoxic therapy or ionizing radiotherapy for an unrelated disease2,3

Cytotoxic therapies associated with development of t-AML3-7,a:

t-AML patient caseb

t-AML patient

Name

Mary

Age

60

Search icon

Diagnosis

t-AML

Folder icon

Prior therapy

Radiotherapy and an R-CVP regimen for follicular lymphoma

INDICATION

VYXEOS (daunorubicin and cytarabine) liposome for injection 44 mg/100 mg is indicated for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC).

IMPORTANT SAFETY INFORMATION

INDICATION

VYXEOS (daunorubicin and cytarabine) liposome for injection 44 mg/100 mg is indicated for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC).

Important Safety Information

WARNING: DO NOT INTERCHANGE WITH OTHER DAUNORUBICIN AND/OR CYTARABINE-CONTAINING PRODUCTS

VYXEOS has different dosage recommendations than daunorubicin hydrochloride injection, cytarabine injection, daunorubicin citrate liposome injection, and cytarabine liposome injection. Verify drug name and dose prior to preparation and administration to avoid dosing errors.